RT Book, Section
A1 Damon, Lloyd E.
A1 Andreadis, Charalambos Babis
A2 Papadakis, Maxine A.
A2 McPhee, Stephen J.
A2 Rabow, Michael W.
A2 McQuaid, Kenneth R.
SR Print(0)
ID 1184166362
T1 Hodgkin Lymphoma
T2 Current Medical Diagnosis & Treatment 2022
YR 2022
FD 2022
PB McGraw-Hill Education
PP New York, NY
SN 9781264269389
LK accessmedicine.mhmedical.com/content.aspx?aid=1184166362
RD 2024/04/24
AB Key  Clinical  Updates  in  Hodgkin  LymphomaABVD  (doxorubicin,  bleomycin,  vinblastine,  dacarbazine)  chemotherapy  remains  the  standard  first-line  regimen.  The  substitution  of  the  antibody-drug  conjugate  brentuximab  vedotin  for  bleomycin  (AAVD)  has  demonstrated  superior  progression-free  survival  to  ABV  but  no  change  in  overall  survival.